Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is in a strong position with a successful Papzimeos launch, potential label expansions, and a pipeline of promising treatments. The company's financial outlook is positive with revenue growth projected for the coming years and a clear path to reaching cash flow break-even by the end of 2026. Risks to this outlook include setbacks in clinical trials, potential regulatory challenges, and competition in the market. However, overall, Precigen's strong product portfolio and strategic position make it a promising investment opportunity.

Bears say

Precigen is facing several challenges with its pipeline, including delays in data release, lack of diversity in its development programs, and potential competition in the immuno-oncology and gene therapy fields. With weak financial performance and a lack of compelling data, it is uncertain if Precigen's technology platforms can deliver on its promise to revolutionize precision medicine, making it a risky investment opportunity. As a result, a negative outlook is warranted for Precigen's stock.

Precigen (PGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Precigen (PGEN) has a Buy consensus rating as of Sep 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.